ChemoCentryx, Inc. (NASDAQ:CCXI)‘s stock had its “hold” rating reaffirmed by equities researchers at Cowen and Company in a note issued to investors on Tuesday.

The analysts wrote, “ChemoCentryx reported Q2 financials, including a net loss of $9.2MM and a June 30.””

Separately, Zacks Investment Research raised ChemoCentryx from a “hold” rating to a “buy” rating and set a $12.00 price objective on the stock in a report on Monday, July 17th.

Shares of ChemoCentryx (NASDAQ:CCXI) traded down 2.41% on Tuesday, hitting $10.14. The company had a trading volume of 126,434 shares. The company has a 50 day moving average price of $9.47 and a 200 day moving average price of $7.68. ChemoCentryx has a 1-year low of $3.95 and a 1-year high of $10.80. The firm’s market capitalization is $488.47 million.

ChemoCentryx (NASDAQ:CCXI) last issued its quarterly earnings data on Wednesday, May 10th. The biopharmaceutical company reported ($0.12) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.26) by $0.14. The company had revenue of $8.23 million for the quarter. On average, equities analysts forecast that ChemoCentryx will post ($0.69) earnings per share for the current fiscal year.

COPYRIGHT VIOLATION WARNING: “ChemoCentryx, Inc. (CCXI) Given Hold Rating at Cowen and Company” was reported by American Banking News and is the property of of American Banking News. If you are viewing this report on another site, it was illegally stolen and republished in violation of US and international copyright & trademark laws. The legal version of this report can be viewed at

In related news, insider Petrus Bekker sold 19,877 shares of the stock in a transaction dated Monday, July 10th. The stock was sold at an average price of $9.30, for a total transaction of $184,856.10. Following the sale, the insider now owns 79,426 shares of the company’s stock, valued at approximately $738,661.80. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders have sold a total of 223,649 shares of company stock worth $2,157,360 in the last three months. 26.80% of the stock is currently owned by insiders.

Several hedge funds have recently added to or reduced their stakes in the stock. Bank of Montreal Can acquired a new stake in ChemoCentryx during the second quarter valued at $102,000. Trexquant Investment LP boosted its stake in ChemoCentryx by 81.1% in the second quarter. Trexquant Investment LP now owns 18,600 shares of the biopharmaceutical company’s stock valued at $174,000 after buying an additional 8,327 shares during the last quarter. State of Wisconsin Investment Board acquired a new stake in ChemoCentryx during the second quarter valued at $178,000. Dynamic Technology Lab Private Ltd acquired a new stake in ChemoCentryx during the first quarter valued at $189,000. Finally, First Quadrant L P CA acquired a new stake in ChemoCentryx during the second quarter valued at $219,000. 49.57% of the stock is currently owned by hedge funds and other institutional investors.

About ChemoCentryx

ChemoCentryx, Inc is a biopharmaceutical company. The Company is engaged in developing new medications targeted at inflammatory disorders, autoimmune diseases and cancer. Each of its drug candidates focuses on a specific chemoattractant receptor that selectively blocks its negative inflammatory or suppressive response, leaving the rest of the immune system intact.

Receive News & Ratings for ChemoCentryx Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ChemoCentryx Inc. and related companies with's FREE daily email newsletter.